|
1
|
Mirabello L, Troisi RJ and Savage SA:
International osteosarcoma incidence patterns in children and
adolescents, middle ages and elderly persons. Int J Cancer.
125:229–234. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Misaghi A, Goldin A, Awad M and Kulidjian
AA: Osteosarcoma: A comprehensive review. SICOT J. 4:122018.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nusse R, van Ooyen A, Cox D, Fung YK and
Varmus H: Mode of proviral activation of a putative mammary
oncogene (int-1) on mouse chromosome 15. Nature. 307:131–136. 1984.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nusse R: Wnt signaling in disease and in
development. Cell Res. 15:28–32. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sato A, Yamamoto H, Sakane H, Koyama H and
Kikuchi A: Wnt5a regulates distinct signalling pathways by binding
to Frizzled2. EMBO J. 29:41–54. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
He X, Saint-Jeannet JP, Wang Y, Nathans J,
Dawid I and Varmus H: A member of the Frizzled protein family
mediating axis induction by Wnt-5A. Science. 275:1652–1654. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ishikawa T, Tamai Y, Zorn AM, Yoshida H,
Seldin MF, Nishikawa S and Taketo MM: Mouse Wnt receptor gene Fzd5
is essential for yolk sac and placental angiogenesis. Development.
128:25–33. 2001.PubMed/NCBI
|
|
8
|
Zhu Y, Tian Y, Du J, Hu Z, Yang L, Liu J
and Gu L: Dvl2-dependent activation of Daam1 and RhoA regulates
Wnt5a-induced breast cancer cell migration. PLoS One. 7:e378232012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu G, Yan T, Li X, Sun J, Zhang B, Wang H
and Zhu Y: Daam1 activates RhoA to regulate Wnt5a-induced
glioblastoma cell invasion. Oncol Rep. 39:465–472. 2018.PubMed/NCBI
|
|
10
|
Yan T, Zhang A, Shi F, Chang F, Mei J, Liu
Y and Zhu Y: Integrin αvβ3-associated DAAM1 is essential for
collagen-induced invadopodia extension and cell haptotaxis in
breast cancer cells. J Biol Chem. 293:10172–10185. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yu J, Chen L, Cui B, Widhopf GF II, Shen
Z, Wu R, Zhang L, Zhang S, Briggs SP and Kipps TJ: Wnt5a induces
ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and
proliferation. J Clin Invest. 126:585–598. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang A, Yan T, Wang K, Huang Z and Liu J:
PI3Kα isoform-dependent activation of RhoA regulates Wnt5a-induced
osteosarcoma cell migration. Cancer Cell Int. 17:272017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dai B, Yan T and Zhang A: ROR2 receptor
promotes the migration of osteosarcoma cells in response to Wnt5a.
Cancer Cell Int. 17:1122017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xiong H, Yan T, Zhang W, Shi F, Jiang X,
Wang X, Li S, Chen Y, Chen C and Zhu Y: miR-613 inhibits cell
migration and invasion by downregulating Daam1 in triple-negative
breast cancer. Cell Signal. 44:33–42. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hasan MK, Yu J, Widhopf GF II, Rassenti
LZ, Chen L, Shen Z, Briggs SP, Neuberg DS and Kipps TJ: Wnt5a
induces ROR1 to recruit DOCK2 to activate Rac1/2 in chronic
lymphocytic leukemia. Blood. 132:170–178. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yu J, Chen L, Cui B, Wu C, Choi MY, Chen
Y, Zhang L, Rassenti LZ, Widhopf Ii GF and Kipps TJ: Cirmtuzumab
inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic
leukemia treated with ibrutinib. Leukemia. 31:1333–1339. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yu J, Chen Y, Chen L, Zhang L, Rassenti
LZ, Widhopf GF II and Kipps TJ: Cirmtuzumab inhibits
ibrutinib-resistant, Wnt5a-induced Rac1 activation and
proliferation in mantle cell lymphoma. Oncotarget. 9:24731–24736.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Choi MY, Widhopf GF II, Wu CC, Cui B, Lao
F, Sadarangani A, Cavagnaro J, Prussak C, Carson DA, Jamieson C and
Kipps TJ: Pre-clinical specificity and safety of UC-961, a
first-in-class monoclonal antibody targeting ROR1. Clin Lymphoma
Myeloma Leuk (15 Suppl). S167–S169. 2015. View Article : Google Scholar
|
|
19
|
Wu X, Yan T, Hao L and Zhu Y: Wnt5a
induces ROR1 and ROR2 to activate RhoA in esophageal squamous cell
carcinoma cells. Cancer Manag Res. 11:2803–2815. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Choi MY, Widhopf GF II, Ghia EM, Kidwell
RL, Hasan MK, Yu J, Rassenti LZ, Chen L, Chen Y, Pittman E, et al:
Phase I trial: Cirmtuzumab inhibits ROR1 signaling and stemness
signatures in patients with chronic lymphocytic leukemia. Cell Stem
Cell. 22:951.e3–959.e3. 2018. View Article : Google Scholar
|
|
21
|
Hasegawa D, Wada N, Yoshida S, Mitarai H,
Arima M, Tomokiyo A, Hamano S, Sugii H and Maeda H: Wnt5a
suppresses osteoblastic differentiation of human periodontal
ligament stem cell-like cells via Ror2/JNK signaling. J Cell
Physiol. 233:1752–1762. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fritsch R and Downward J: SnapShot: Class
I PI3K isoform signaling. Cell. 154:940–940.e1. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Linnerth-Petrik NM, Santry LA, Moorehead
R, Jücker M, Wootton SK and Petrik J: Akt isoform specific effects
in ovarian cancer progression. Oncotarget. 7:74820–74833. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhu Y, Shen T, Liu J, Zheng J, Zhang Y, Xu
R, Sun C, Du J, Chen Y and Gu L: Rab35 is required for
Wnt5a/Dvl2-induced Rac1 activation and cell migration in MCF-7
breast cancer cells. Cell Signal. 25:1075–1085. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu J, Zhang Y, Xu R, Du J, Hu Z, Yang L,
Chen Y, Zhu Y and Gu L: PI3K/Akt-dependent phosphorylation of GSK3β
and activation of RhoA regulate Wnt5a-induced gastric cancer cell
migration. Cell Signal. 25:447–456. 2013. View Article : Google Scholar : PubMed/NCBI
|
